If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIntercede Regulatory News (IGP)

Share Price Information for Intercede (IGP)

Share Price is delayed by 15 minutes
Get Live Data
103.50    -2.00 (-1.90%)
Bid:
102.00
Ask:
105.00
Spread: 3.00 (2.941%)
Market Cap: £62.27m
IGP Live PriceLast checked at - London Stock Exchange

Intraday Intercede Share Chart

Positive Trading Update

7 Sep 2010 07:00

RNS Number : 2445S
Intercede Group PLC
07 September 2010
 



7 September 2010

Intercede Group plc

("Intercede")

 

Positive Trading Update

 

Intercede announces strong levels of business throughout the summer period.

The Healthcare sector has made a significant contribution to revenue and in July orders from an existing UK customer generated more than £800,000 in cash receipts. 

US government customers have continued to buy additional software licenses and a further US Federal Agency has purchased the Intercede MyID system. This brings the total number of Agencies using Intercede MyID for HSPD-12/PIV compliance to 13. Lockheed Martin and FAA continue to buy materially significant quantities of professional service time from Intercede in support of their large enterprise-wide identity programs.

Internationally, Intercede has added the Australian government and a South African bank to its customer list. Additional revenues are accruing for the next phase of the Kuwait national ID program and an existing customer that has purchased Intercede MyID to power a Switzerland-wide electronic identity service.

Intercede's sales activities continue to increase the pipeline of future business. A number of contract awards are also pending imminent closure, and the company is on target to meet full year expectations. Intercede remains in a strong cash position at the end of August.

Richard Parris, Chairman and Chief Executive of Intercede, said:

"Our level of business activity is at an all time high driven by repeat orders against existing contracts, new orders from new customers and a growing pipeline of high value prospects. Although, as expected, we have seen a reduction in UK Government orders compared to the same period last year, this is being compensated for by international orders, particularly from the US."

About Intercede

Intercede is the producer of the MyID Identity and Credential Management System (IDCMS). Intercede's MyID is the only IDCMS software product that enables organisations to easily and securely manage the identities of people and their associated identity credentials within a single, integrated, workflow driven platform. This includes enabling and managing: secure registration, biometric capture, application vetting and approval through to smart card personalisation, issuance and management.

Intercede's MyID is being used around the world by large corporations, governments and banks to manage millions of identities for employees, citizens and customers. Notable deployments in the US include more than 10 Federal Agencies, a program with Lockheed Martin and two major US financial institutions. In Europe and the Middle East, Intercede's MyID is being deployed in support of government identity, health and corporate employee ID security projects.

For more information visit http://www.intercede.com

 

ENQUIRIES

 

Intercede Group plc

Tel. +44 (0)1455 558111

Richard Parris, Chairman & Chief Executive

Andrew Walker, Finance Director

FinnCap

Tel. + 44 (0)20 7600 1658

Clive Carver

Sarah Wharry

Pelham Bell Pottinger

Tel. +44 (0)20 7861 3112

Archie Berens

Francesca Tuckett

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTKKADDFBKDKCK
Date   Source Headline
15th Sep 20212:09 pmRNSResult of AGM
15th Sep 20217:00 amRNSMultiple Customers choose to Upgrade MyID
20th Jul 20217:00 amRNSIntercede achieves FIDO2 certification
5th Jul 20217:00 amRNSConnect Partner Programme & Q1 Contract Wins
15th Jun 20218:26 amRNSIssue of Equity
8th Jun 20217:00 amRNSFinal Results
2nd Jun 202110:09 amRNSInvestor Presentation
10th May 20217:00 amRNSShare Incentive Plan
7th Apr 20217:00 amRNSTrading Update & Appointment of Auditor
1st Apr 202110:30 amRNSReceipt of $3.4m Order
10th Mar 20217:00 amRNSShare Incentive Plan
23rd Feb 20217:00 amRNSAmendment to LTIP
22nd Feb 20214:10 pmRNSHolding(s) in Company
16th Feb 20217:00 amRNSCLN Conversion to Equity
12th Feb 20217:00 amRNSHolding(s) in Company
8th Feb 202112:40 pmRNSHolding(s) in Company
4th Feb 20217:00 amRNSCLN Call & Issue of Equity
11th Jan 20217:00 amRNSNew Contract Win
5th Jan 202111:00 amRNSCLN Conversion to Equity
4th Jan 202110:40 amRNSHolding(s) in Company
22nd Dec 20207:00 amRNSNew Contract Win
24th Nov 20207:00 amRNSHalf-year Report
17th Nov 20207:00 amRNSContract Win: Follow-on Purchase Order
12th Nov 20207:00 amRNSInvestor Presentation
8th Oct 20207:01 amRNSIntercede join the FIDO Alliance
8th Oct 20207:00 amRNSTrading Update
16th Sep 20203:40 pmRNSResult of AGM
20th Aug 20207:05 amRNSContract Win - Initial Progress Order
5th Aug 20202:01 pmRNSHolding(s) in Company
30th Jul 20207:00 amRNSContract Win
2nd Jun 20207:00 amRNSFinal Results
12th May 20207:00 amRNSShare Incentive Plan
20th Apr 202010:02 amRNSDirector/PDMR Shareholding
14th Apr 20207:00 amRNSDirector/PDMR Shareholding
7th Apr 20207:00 amRNSTrading Update
3rd Apr 20205:07 pmRNSShare Incentive Plan
31st Mar 20207:00 amRNSReceipt of $4.6m Order
28th Feb 20207:00 amRNSShare Incentive Plan
26th Feb 20209:50 amRNSShare Incentive Plan
25th Feb 20207:00 amRNSShare Incentive Plan
12th Feb 202011:22 amRNSShare Award
25th Nov 20197:00 amRNSHalf-year Report
7th Oct 20197:00 amRNSTrading Update
30th Sep 20197:00 amRNSDirector/PDMR Shareholding
18th Sep 20196:30 pmRNSResult of AGM
16th Sep 20193:56 pmRNSPosting of Annual Report & Notice of AGM
17th Jun 20197:00 amRNSAppointment of Non-Executive Director
5th Jun 20197:00 amRNSFinal Results
8th Apr 20197:00 amRNSSale of Property
2nd Apr 20197:00 amRNSTrading Update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.